http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2593010-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f475099b0de77dbfc3c4c6a988fc717 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2545-114 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2521-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2537-143 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-701 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6888 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6851 |
| filingDate | 2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61585f27d1886e9e1fe98147e98e9eb0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc3b0531af37d1ad596c244eafc557bc |
| publicationDate | 2021-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2593010-A |
| titleOfInvention | Composition and method |
| abstract | A kit for determining the presence or absence of SARS-CoV-2 in a sample. The kit comprises a pair of polynucleotide primers having the sequences shown in SEQ ID NOs 1 and 2, as well as a polynucleotide probe having the sequence shown in SEQ ID NO 3. The primers and probe are specific to the ORF1ab gene. The probe can be a DNA probe, a TaqMan® probe, a molecular probe, or a scorpion probe. The probe can be detectably labelled. The probe can be labelled with a fluorescent molecule or dye or 6-carboxyfluorescein (FAM). Further aspects of the invention are methods of detecting SARS-CoV-2 using the kit by conducting a reverse transcription polymerase chain reaction (rtPCR) assay. The rtPCR assay can be a one step rtPCR assay conducted in a tube or vessel. The method can comprise extracting RNA from the sample before conducting the rtPCR assay. The sample can be human. The sample can be a nasopharyngeal sample, a saliva sample, or a blood sample. A further aspect can be a method of measuring the SARS-CoV-2 titre in a sample or a patient. A further aspect can be a method of determining whether a patient is infected with SARS-CoV-2. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2772362-C1 |
| priorityDate | 2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 259.